Cuma Aytekin

Cuma Aytekin

Auto-generated profile, based on publicly available information

Cuma Aytekin

Mersin Universitesi

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2017 in The Aging Male
Verified
Journal Article
Closed access
EAErdem Akbay
Erdem Akbay
MBMurat Bozlu
Murat Bozlu
SÇSelahittin Çayan
Selahittin Çayan
PÖPınar Pelin Özcan
Pınar Pelin Özcan
MTMesut Tek
Mesut Tek
CACuma Aytekin
Cuma Aytekin
Introduction: The aim of this study is to evaluate prostate-specific antigen decline pattern including prostate-specific antigen kinetics following androgen deprivation therapy on prostate-specific antigen progression in the patients with advanced prostate cancer. Materials and methods: Ninety-seven advanced prostate cancer patients receiving maximum androgen deprivation therapy were enrolled in case–control study. Baseline prostate-specific antigen, Gleason Score, bone metastase, nadir prostate-specific antigen, time to nadir prostate-specific antigen, declining slope to nadir prostate-specific antigen, estimated baseline prostate-specific antigen half-time, current prostate-specific antigen, post-nadir prostate-specific antigen time, estimated prostate-specific antigen, estimated decline of baseline prostate-specific antigen as quantitative, and ratio were recorded and calculated. Results: The ratio of prostate-specific antigen progression was significantly lower at the patients who had slower declining slope to prostate-specific antigen, longer time to nadir prostate-specific antigen, and lower estimated decline ratio of baseline prostate-specific antigen (p: .016, p: .020, and p: .026, respectively). Conclusions: The shorter time to nadir prostate-specific antigen following androgen deprivation therapy, faster declining slope to nadir prostate-specific antigen and higher estimated decline ratio of baseline prostate-specific antigen are associated with higher risk of disease progression in patients with hormone-sensitive prostate cancer.

19 September 2026 in BMC Urology
Verified
Journal Article
Open access
PDF file
ANAli Nebioğlu
Ali Nebioğlu
CACuma Ayteki̇n
Cuma Ayteki̇n
ATAhmet Turhan
Ahmet Turhan
MBMurat Bozlu
Murat Bozlu
HDHasan Erdal Doruk
Hasan Erdal Doruk
To evaluate the association between metformin exposure and oncological outcomes in bacillus Calmette–Guérin (BCG)-treated non-muscle-invasive bl

27 March 2026 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
ATAhmet Turhan
Ahmet Turhan
EDElife Kettaş Dölek
Elife Kettaş Dölek
TATolga Açıkal
Tolga Açıkal
CACuma Aytekin
Cuma Aytekin
EAErdem Akbay
Erdem Akbay
EEErim Erdem
Erim Erdem

18 June 2026 in Urologia Internationalis
Verified
Journal Article
Closed access
CACuma Aytekin
Cuma Aytekin
MBMert Başaranoğlu
Mert Başaranoğlu
ATAhmet Turhan
Ahmet Turhan
EAErdem Akbay
Erdem Akbay
EEErim Erdem
Erim Erdem
Introduction Persistent lower urinary tract symptoms (LUTS) in young adults following childhood primary nocturnal enuresis (PNE) refractory to desmopressin represent an undercharacterized condition at the pediatric-adult care interface. No prior study has compared pharmacotherapy options in this specific population. Methods We performed a retrospective, single-center, hypothesis-generating comparative cohort study at a tertiary urology center (January 2017–September 2025). Male adults aged 18–35 years with documented childhood primary nocturnal enuresis (PNE) based on International Children's Continence Society (ICCS) criteria, desmopressin treatment failure, and persistent storage-phase lower urinary tract symptoms (LUTS) were included. Patients received mirabegron 25–50 mg daily (Group A, n=33) or anticholinergic therapy (Group B, n=32). The primary outcome was categorical treatment response (complete ≥75%, partial 50–74%, minimal 25–49%, failure <25%). Secondary outcomes included nocturia, urgency, micturition frequency, incontinence episodes, International Prostate Symptom Score (IPSS), quality of life, and adverse events. Analyses used independent t-tests, chi-square/Fisher exact tests, paired t-tests, and analysis of covariance (ANCOVA). Results Baseline characteristics were comparable between groups. Childhood nonmonosymptomatic enuresis (NMSE) phenotype was prevalent in 86.2% of patients, with reduced functional bladder capacity documented in 86.2%. Mirabegron achieved higher overall clinical benefit (≥50% improvement) than anticholinergics (78.8% vs. 56.3%, p=0.042) and higher complete response rates (24.2% vs. 6.3%, p=0.044). Symptom reductions consistently favored mirabegron: nocturia 51% vs. 38% (p=0.031), urgency 48% vs. 36% (p=0.024), micturition frequency 37% vs. 26% (p=0.018), and quality of life improvement 58% vs. 38% (p=0.009). Safety profiles were comparable with no serious adverse events and similar treatment persistence (90.9% vs. 87.5%, p=0.642). Conclusion Pending prospective confirmation, mirabegron provides superior efficacy with comparable safety versus anticholinergic therapy in male adults with persistent LUTS after desmopressin-refractory childhood PNE, supporting β3-adrenergic agonist therapy as a promising option for this underserved transitional population.

25 May 2023 in Journal of Ankara University Faculty of Medicine
Verified
Journal Article
Closed access
CÖCihat Özcan
Cihat Özcan
SSSelçuk Sarıkaya
Selçuk Sarıkaya
CACuma Aytekin
Cuma Aytekin
BTBahadır Topuz
Bahadır Topuz
SBSelahattin Bedir
Selahattin Bedir

12 May 2026 in İstanbul Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
CACuma Aytekin
Cuma Aytekin
OBOsman Bozkurt
Osman Bozkurt
HAHakan Anıl
Hakan Anıl
BKBarış Kartal
Barış Kartal
MBMert Başaranoğlu
Mert Başaranoğlu
NŞNevzat Şener
Nevzat Şener
Objective: This study aimed to evaluate the safety of percutaneous nephrolithotomy (PNL) following normalization of procalcitonin (PCT) levels in kidney stone patients with recurrent urinary tract infections (rUTIs) and assess the diagnostic performance of PCT in predicting postoperative infective complications.Materials and Methods: A prospective cohort study was conducted between January 2020 and December 2024, including 29 kidney stone patients with a history of rUTI and persistent infection despite multiple antibiotic regimens. PNL was performed after normalization of serum PCT levels (38.5°C, PCT >2.0 ng/mL with clinical signs of infection, or positive blood culture); secondary endpoints included overall complication rate, stone-free rate, and length of hospital stay. The diagnostic performance of PCT was evaluated using ROC curve analysis.Results: The mean age was 48.1±14.4 years, with 51.7% male patients. The average stone size was 31.1±14.1 mm. extendedspectrum betalactamase (ESBL)-producing E. coli was the most common preoperative pathogen (72.4%). Preoperative PCT median value was 0.06 ng/mL (range 0.01-0.24), with all patients within normal limits. All patients underwent successful PNL (mean operative time: 78.5±15.2 minutes). Postoperatively, infectious complications occurred in 3 patients (10.3%), with no cases of sepsis or septic shock. ROC analysis revealed an AUC of 0.887 (95% CI: 0.743–1.000, p=0.032), with an optimal cut-off value of 1.5 ng/mL (sensitivity: 100%, specificity: 89.3%). The stone-free rate was 55.2%, and the mean hospital stay was 2.7±1.04 days.Conclusion: PNL guided by PCT is a safe and effective treatment in patients with rUTI. PCT is a valuable biomarker for predicting postoperative infections and supporting surgical decision-making in high-risk patients.